abstract: BACKGROUND AND PURPOSE: @entity1652 ( @entity1652 ) are a group of rare @entity6220 . The identification of specific antibodies directed to @entity3951 ( @entity3951 -IgG) led to the distinction from @entity15 . However, up to 25% of the clinically diagnosed NMO @entity1 are seronegative for @entity3951 -IgG. A subgroup of these @entity1 might be identified by antibodies directed to @entity3950 ( @entity3950 -IgG). Our objective was to investigate whether the clinical characteristics of these @entity1 differ. METHODS: Using a cell-based assay, samples of 61 @entity3951 -IgG seronegative @entity1 and 41 @entity3951 -IgG seropositive @entity1 with clinically NMOSD were analysed for the presence of @entity3950 -IgG. Clinical characteristics of the @entity3951 -IgG, @entity3950 -IgG seropositive and double seronegative NMOSD @entity1 were compared. RESULTS: Twenty of the 61 @entity3951 -IgG seronegative @entity1 tested @entity3950 -IgG seropositive (33%). @entity3950 -IgG seropositive @entity1 were more frequently males in contrast to @entity3951 -IgG seropositive @entity1 (55% vs. 15%, P < 0.01) and Caucasians (90% vs. 63%, P = 0.03). They more frequently presented with coincident @entity7995 and transverse @entity4685 (40% vs. 12%, P = 0.02) and had a monophasic disease course (70% vs. 29%, P < 0.01). @entity3951 -IgG seropositive @entity1 were 2.4 times more likely to suffer from relapses compared with @entity3950 -IgG seropositive @entity1 (relative risk 2.4, 95% confidence interval 1.2-4.7). @entity3951 -IgG seropositive @entity1 had higher Expanded Disability Status Scale levels at last follow-up (P < 0.01). CONCLUSION: Antibodies directed to @entity3950 identify a subgroup of @entity3951 -IgG seronegative NMO @entity1 with generally a favourable monophasic disease course.

title: XXXX : comparison of clinical and magnetic resonance imaging characteristics of @entity3951 -IgG versus @entity3950 -IgG seropositive cases in the Netherlands.

answer: @entity1652 :: (MESH:D009471,Disease) :: ['Neuromyelitis optica spectrum disorders']


abstract: INTRODUCTION: The treatment of massive @entity1151 with an associated @entity1167 is controversial; however, surgical thrombectomy with extracorporeal circulation (ECC) is an option for treatment. It is difficult to remove all @entity1031 material. Theoretically, retrograde blood perfusion through the lungs may be beneficial. OBJECTIVES: To investigate whether retrograde blood perfusion through the lungs during a thrombectomy is beneficial. METHODS: Twelve @entity1707 were prepared for ECC. Repetitive injections of preformed blood thrombi into the right atrium resulted in @entity1167 . ECC was established after 10minutes of @entity1167 , and after a sternotomy, the main pulmonary artery was incised and as much thrombotic material as possible was removed from the pulmonary arteries. The @entity1707 were randomised to ECC for one hour either with or without retrograde perfusion in the pulmonary circulation. After one hour, the released material was removed from the pulmonary arteries, and the incision was sutured. The @entity1707 were weaned from the ECC. After sacrificing the @entity1707 , they were autopsied with special attention to the amount of remaining thrombi. Additional histological analyses were performed with special attention to microembolisms, atelectases, and signs of @entity3145 . RESULTS: All of the @entity1707 were weaned from the ECC. The amount of the embolic material removed varied considerably, as did the amount removed after the retrograde or antegrade perfusion, and there was no significant difference between the two treatment modalities. There were no signs of @entity3145 in the lungs. CONCLUSIONS: Retrograde lung perfusion was not generally beneficial in the treatment of massive @entity1151 in this setup; however, it may be an option if only a modest amount of material is accessible in the pulmonary artery.

title: Retrograde lung perfusion in the treatment of massive XXXX . A randomised porcine study.

entities_list: @entity3145 :: ('MESH:D017695', 'Disease') :: ['tissue damage']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism', 'pulmonary embolisms']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest', 'cardiac arrests']

answer: @entity1151 :: (MESH:D011655,Disease) :: ['pulmonary embolism']


abstract: Asphyxiating @entity1514 is an uncommon condition with multiple organ afectation and high neonatal mortality. It presents with @entity851 , short extremities, narrow thorax. With growth, there is respiratory improvement, but emergence of @entity8 . OBJECTIVE: to describe the long-term evolution of 8 @entity1 of a pediatric hospital. METHODS: we retrospectively evaluated age at diagnosis, sex, anthropometric variables, complications and radiology. RESULTS: male/female 6/2. Median age at diagnosis: 2.54 years. EVOLUTION: 8/8 respiratory compromise, 3/8 kidney, liver 2/8, 1/8 ophthalmologic, cardiac 1/8. Median height at diagnosis -1.76 DS, normal postnatal growth and body proportions. Radiology: 8/8 narrow chest and brachyphalangia in hands. 5/8 acetabular abnormalities. DISCUSSION: for surveillance it is recommended to monitor @entity177 . The pediatrician should suspect this entity in a newborn with @entity649 .

title: [Clinical, radiological and auxologic long-term evolution of 8 @entity1 with asphyxiating XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal, hepatic, pancreatic and/or retinal impairment']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['short stature']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['narrow thorax and respiratory distress']

entities_list: @entity1514 :: ('MESH:D013896', 'Disease') :: ['Thoracic Dysplasia']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal, liver and eye function']

answer: @entity1514 :: (MESH:D013896,Disease) :: ['thoracic dysplasia']


abstract: Asphyxiating @entity1514 is an uncommon condition with multiple organ afectation and high neonatal mortality. It presents with @entity851 , short extremities, narrow thorax. With growth, there is respiratory improvement, but emergence of @entity8 . OBJECTIVE: to describe the long-term evolution of 8 @entity1 of a pediatric hospital. METHODS: we retrospectively evaluated age at diagnosis, sex, anthropometric variables, complications and radiology. RESULTS: male/female 6/2. Median age at diagnosis: 2.54 years. EVOLUTION: 8/8 respiratory compromise, 3/8 kidney, liver 2/8, 1/8 ophthalmologic, cardiac 1/8. Median height at diagnosis -1.76 DS, normal postnatal growth and body proportions. Radiology: 8/8 narrow chest and brachyphalangia in hands. 5/8 acetabular abnormalities. DISCUSSION: for surveillance it is recommended to monitor @entity177 . The pediatrician should suspect this entity in a newborn with @entity649 .

title: [Clinical, radiological and auxologic long-term evolution of 8 XXXX with asphyxiating @entity1514 ].

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: Vaccination against @entity683 is recommended in @entity1 with @entity454 ( @entity454 ). However, so far, no systematic review has summarized the available evidence on the effectiveness and safety of @entity683 vaccination in this @entity1 group. METHODS: We conducted a systematic review and meta-analysis and assessed the quality of evidence using the GRADE methodology. We searched MEDLINE, EMBASE, Cochrane Library databases, ClinicalTrials.gov, and reference lists for studies on efficacy, effectiveness, and/or safety of seasonal @entity683 vaccination in @entity1 with @entity454 receiving dialysis. All reported clinical outcomes were considered, including all-cause mortality, @entity204 , @entity204 , all-cause hospitalization, hospitalization due to @entity55 , hospitalization due to @entity2259 , @entity646 , or @entity295 , hospitalization due to @entity1729 , ICU admission, and @entity683 . RESULTS: Five observational studies and no randomized-controlled trial were identified. In four studies, risk of bias was high regarding all reported outcomes. Strong residual confounding was likely to be present in one study reporting on three outcomes, as indicated by significant protective effects of vaccination outside @entity683 seasons. Therefore, the statistically significant protective effects on all-cause mortality ( @entity6831 ( @entity6831 ), 32%; 95% CI, 24-39%), @entity204 ( @entity6831 , 16%; 95% CI, 1-29%), hospitalization due to @entity55 ( @entity6831 , 14%; 95% CI, 7-20%), ICU admission ( @entity6831 , 81%; 95% CI, 63-86%), and @entity683 ( @entity6831 , 12%; 95% CI, 10-14%) have to be taken with caution. According to GRADE, the quality of the body of evidence was considered very low for all outcomes. No study reported on laboratory-confirmed @entity778 or on safety endpoints. CONCLUSIONS: Evidence on the protective effects of @entity683 vaccination in @entity1 with @entity454 is limited and of very low quality. Since @entity6831 estimates in the available literature are prone to unmeasured confounding, studies using randomization or quasi-experimental designs are needed to determine the extent by which vaccination prevents @entity683 and related clinical outcomes in this at-risk population. However, given the high rates of health-endangering events in these @entity1 , even a low @entity6831 can be considered as sufficient to recommend annual @entity683 vaccination.

title: Influenza vaccination in @entity1 with XXXX : systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['influenza virus infections']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['influenza or pneumonia']

entities_list: @entity6831 :: ('MESH:D004673', 'Disease') :: ['VE', 'vaccine effectiveness']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza', 'influenza-like illness']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory infection']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death', 'infectious death']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

answer: @entity454 :: (MESH:D007676,Disease) :: ['end-stage renal disease']


abstract: BACKGROUND: Vaccination against @entity683 is recommended in @entity1 with @entity454 ( @entity454 ). However, so far, no systematic review has summarized the available evidence on the effectiveness and safety of @entity683 vaccination in this @entity1 group. METHODS: We conducted a systematic review and meta-analysis and assessed the quality of evidence using the GRADE methodology. We searched MEDLINE, EMBASE, Cochrane Library databases, ClinicalTrials.gov, and reference lists for studies on efficacy, effectiveness, and/or safety of seasonal @entity683 vaccination in @entity1 with @entity454 receiving dialysis. All reported clinical outcomes were considered, including all-cause mortality, @entity204 , @entity204 , all-cause hospitalization, hospitalization due to @entity55 , hospitalization due to @entity2259 , @entity646 , or @entity295 , hospitalization due to @entity1729 , ICU admission, and @entity683 . RESULTS: Five observational studies and no randomized-controlled trial were identified. In four studies, risk of bias was high regarding all reported outcomes. Strong residual confounding was likely to be present in one study reporting on three outcomes, as indicated by significant protective effects of vaccination outside @entity683 seasons. Therefore, the statistically significant protective effects on all-cause mortality ( @entity6831 ( @entity6831 ), 32%; 95% CI, 24-39%), @entity204 ( @entity6831 , 16%; 95% CI, 1-29%), hospitalization due to @entity55 ( @entity6831 , 14%; 95% CI, 7-20%), ICU admission ( @entity6831 , 81%; 95% CI, 63-86%), and @entity683 ( @entity6831 , 12%; 95% CI, 10-14%) have to be taken with caution. According to GRADE, the quality of the body of evidence was considered very low for all outcomes. No study reported on laboratory-confirmed @entity778 or on safety endpoints. CONCLUSIONS: Evidence on the protective effects of @entity683 vaccination in @entity1 with @entity454 is limited and of very low quality. Since @entity6831 estimates in the available literature are prone to unmeasured confounding, studies using randomization or quasi-experimental designs are needed to determine the extent by which vaccination prevents @entity683 and related clinical outcomes in this at-risk population. However, given the high rates of health-endangering events in these @entity1 , even a low @entity6831 can be considered as sufficient to recommend annual @entity683 vaccination.

title: Influenza vaccination in XXXX with @entity454 : systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The study aim was to determine the association between @entity1 's objectively assessed moderate-to-vigorous physical activity (MVPA) and @entity3457 ( @entity3457 ) and independently mobile trips (IM) during out-of-school hours. METHODS: @entity1 aged 9 to 13 years (n = 254) were recruited from 9 schools in Auckland, New Zealand between 2011 and 2012. @entity1 completed travel diaries and wore accelerometers for 7 days. Parents provided demographic information. Geographic information systems-derived distance to school was calculated. Accelerometer data were extracted for out of school hours only. Percentage of time spent in MVPA (%MVPA), @entity3457 , and IM were calculated. Generalized estimating equations were used to determine the relationship between daily %MVPA and @entity3457 and between daily %MVPA and IM, accounting for age, sex, ethnicity, distance to school, day of the week, and numeric day of data collection. RESULTS: A significant positive relationship was observed between %MVPA and both @entity3457 and IM. For every unit increase in the daily percentage of trips made that were @entity3457 or IM, we found an average increase of 1.28% (95% CI 0.87%, 1.70%) and 1.15% (95% CI 0.71%, 1.59%) time in MVPA, respectively. CONCLUSION: @entity1 's @entity3457 and IM are associated with increased MVPA during out-of-school hours.

title: XXXX 's Out-of-School Independently Mobile Trips, Active Travel, and Physical Activity: A Cross-Sectional Examination from the Kids in the City Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity3457 :: ('OMIM:612348', 'Disease') :: ['AT', 'active trips']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: UNASSIGNED: Cytotoxic anticancer chemotherapy affects pituitary-testicular hormonal axis in @entity1 and in animals. This study investigated the effects on Leydig cells of three cycles of @entity1732 , @entity2879 and @entity900 (0.75, 7.5, and 1.5mg/kg, respectively; @entity12962 ) chemotherapy in @entity35 testis. The chemotherapy has induced @entity1373 of and degenerative changes in Leydig cells at the end of @entity12962 exposure, which remained so even after a recovery time of 63 days. The increased testicular oxidative stress at the end of the chemotherapy returned to normal level after the recovery time. The chemotherapy has stimulated the transcription of @entity15090 ( @entity15090 ), @entity24097 ( @entity24097 ), cytochrome P450 @entity165 side-chain cleavage ( @entity7816 ), @entity31018 , and inhibited that of 17b-hydroxysteroid dehydrogenase ( @entity71789 ) and @entity18946 in association with increased @entity165 and decreased @entity251 levels. Even after the recovery time, the chemotherapy still had inhibitory effects on the transcription of all of the above genes in addition to luteinizing hormone receptor and @entity71790 , but not on the @entity24097 gene. The @entity165 and @entity251 levels also did not show any significant differences with the control group. The decreased @entity251 level at the end of chemotherapy was probably due to inhibition of @entity71790 and @entity71789 genes. In conclusion, clinically relevant dose-levels and treatment protocols of @entity12962 chemotherapy adversely affect Leydig cell function. The @entity12962 chemotherapy inhibits the transcription of steroidogenic enzymes and that these effects sustain over an extended period of time without returning to normal levels.

title: Effects of @entity1732 , @entity2879 and XXXX treatment on Leydig cell structure and transcription of steroidogenic enzymes in @entity35 testis.

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity15090 :: ('25073(Tax:10116)', 'Gene') :: ['scavenger receptor class type-B1', 'SCARB1']

entities_list: @entity24097 :: ('25557(Tax:10116)', 'Gene') :: ['StAR', 'steroidogenic acute-regulatory protein']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: UNASSIGNED: Cytotoxic anticancer chemotherapy affects pituitary-testicular hormonal axis in @entity1 and in animals. This study investigated the effects on Leydig cells of three cycles of @entity1732 , @entity2879 and @entity900 (0.75, 7.5, and 1.5mg/kg, respectively; @entity12962 ) chemotherapy in @entity35 testis. The chemotherapy has induced @entity1373 of and degenerative changes in Leydig cells at the end of @entity12962 exposure, which remained so even after a recovery time of 63 days. The increased testicular oxidative stress at the end of the chemotherapy returned to normal level after the recovery time. The chemotherapy has stimulated the transcription of @entity15090 ( @entity15090 ), @entity24097 ( @entity24097 ), cytochrome P450 @entity165 side-chain cleavage ( @entity7816 ), @entity31018 , and inhibited that of 17b-hydroxysteroid dehydrogenase ( @entity71789 ) and @entity18946 in association with increased @entity165 and decreased @entity251 levels. Even after the recovery time, the chemotherapy still had inhibitory effects on the transcription of all of the above genes in addition to luteinizing hormone receptor and @entity71790 , but not on the @entity24097 gene. The @entity165 and @entity251 levels also did not show any significant differences with the control group. The decreased @entity251 level at the end of chemotherapy was probably due to inhibition of @entity71790 and @entity71789 genes. In conclusion, clinically relevant dose-levels and treatment protocols of @entity12962 chemotherapy adversely affect Leydig cell function. The @entity12962 chemotherapy inhibits the transcription of steroidogenic enzymes and that these effects sustain over an extended period of time without returning to normal levels.

title: Effects of @entity1732 , XXXX and @entity900 treatment on Leydig cell structure and transcription of steroidogenic enzymes in @entity35 testis.

answer: @entity2879 :: (MESH:D005047,Chemical) :: ['etoposide']


abstract: UNASSIGNED: Cytotoxic anticancer chemotherapy affects pituitary-testicular hormonal axis in @entity1 and in animals. This study investigated the effects on Leydig cells of three cycles of @entity1732 , @entity2879 and @entity900 (0.75, 7.5, and 1.5mg/kg, respectively; @entity12962 ) chemotherapy in @entity35 testis. The chemotherapy has induced @entity1373 of and degenerative changes in Leydig cells at the end of @entity12962 exposure, which remained so even after a recovery time of 63 days. The increased testicular oxidative stress at the end of the chemotherapy returned to normal level after the recovery time. The chemotherapy has stimulated the transcription of @entity15090 ( @entity15090 ), @entity24097 ( @entity24097 ), cytochrome P450 @entity165 side-chain cleavage ( @entity7816 ), @entity31018 , and inhibited that of 17b-hydroxysteroid dehydrogenase ( @entity71789 ) and @entity18946 in association with increased @entity165 and decreased @entity251 levels. Even after the recovery time, the chemotherapy still had inhibitory effects on the transcription of all of the above genes in addition to luteinizing hormone receptor and @entity71790 , but not on the @entity24097 gene. The @entity165 and @entity251 levels also did not show any significant differences with the control group. The decreased @entity251 level at the end of chemotherapy was probably due to inhibition of @entity71790 and @entity71789 genes. In conclusion, clinically relevant dose-levels and treatment protocols of @entity12962 chemotherapy adversely affect Leydig cell function. The @entity12962 chemotherapy inhibits the transcription of steroidogenic enzymes and that these effects sustain over an extended period of time without returning to normal levels.

title: Effects of XXXX , @entity2879 and @entity900 treatment on Leydig cell structure and transcription of steroidogenic enzymes in @entity35 testis.

answer: @entity1732 :: (MESH:D001761,Chemical) :: ['bleomycin']


abstract: UNASSIGNED: Cytotoxic anticancer chemotherapy affects pituitary-testicular hormonal axis in @entity1 and in animals. This study investigated the effects on Leydig cells of three cycles of @entity1732 , @entity2879 and @entity900 (0.75, 7.5, and 1.5mg/kg, respectively; @entity12962 ) chemotherapy in @entity35 testis. The chemotherapy has induced @entity1373 of and degenerative changes in Leydig cells at the end of @entity12962 exposure, which remained so even after a recovery time of 63 days. The increased testicular oxidative stress at the end of the chemotherapy returned to normal level after the recovery time. The chemotherapy has stimulated the transcription of @entity15090 ( @entity15090 ), @entity24097 ( @entity24097 ), cytochrome P450 @entity165 side-chain cleavage ( @entity7816 ), @entity31018 , and inhibited that of 17b-hydroxysteroid dehydrogenase ( @entity71789 ) and @entity18946 in association with increased @entity165 and decreased @entity251 levels. Even after the recovery time, the chemotherapy still had inhibitory effects on the transcription of all of the above genes in addition to luteinizing hormone receptor and @entity71790 , but not on the @entity24097 gene. The @entity165 and @entity251 levels also did not show any significant differences with the control group. The decreased @entity251 level at the end of chemotherapy was probably due to inhibition of @entity71790 and @entity71789 genes. In conclusion, clinically relevant dose-levels and treatment protocols of @entity12962 chemotherapy adversely affect Leydig cell function. The @entity12962 chemotherapy inhibits the transcription of steroidogenic enzymes and that these effects sustain over an extended period of time without returning to normal levels.

title: Effects of @entity1732 , @entity2879 and @entity900 treatment on Leydig cell structure and transcription of steroidogenic enzymes in XXXX testis.

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: A 47-year-old female @entity1 with @entity1575 underwent endoscopic injection sclerotherapy for esophageal varices 13  years ago. The @entity1 had no past history of hysterectomy or any other @entity13374 . She was admitted to our hospital because of persistent @entity3556 and exacerbation of @entity417 . A contrast-enhanced computed tomography scan revealed marked dilation of not only the inferior mesenteric vein, but also the left ovarian vein, the uterine vein and the internal iliac vein. A celiac arteriography showed that the blood in the splenic vein was flowing almost totally hepatofugally into the dilated inferior mesenteric vein. An ovarian venography demonstrated knob-shaped dilation of the left ovarian vein draining into the left internal iliac vein. A proximally wedged left ovarian venography visualized the right ovarian vein and the right internal iliac vein with contrast medium via a palisade venous plexus from the dilated uterine and ovarian veins. @entity887 ( @entity887 ) was performed to increase platelet count and to reduce splenic venous blood flow into the ovarian vein. Following the @entity887 , the platelet count increased, and the blood flow in the dilated ovarian vein and uterine vein diminished. In addition, the portal blood flow became hepatopetal, and remarkably increased. There has as yet been no case report in which @entity3556 developed in @entity1 with @entity1575 without any past history of hysterectomy or other @entity13374 . The present case report may be warranted in view of the rarity of the condition.

title: XXXX in a @entity1 with @entity1575 without a past history of laparotomy: successful treatment with partial splenic artery embolization.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient']

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding']

entities_list: @entity13374 :: ('MESH:D005831', 'Disease') :: ['gynecological disorders']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['Partial splenic embolization', 'PSE']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['type C liver cirrhosis', 'liver cirrhosis']

answer: @entity3556 :: (MESH:D014592,Disease) :: ['Vaginal bleeding']


abstract: A 47-year-old female @entity1 with @entity1575 underwent endoscopic injection sclerotherapy for esophageal varices 13  years ago. The @entity1 had no past history of hysterectomy or any other @entity13374 . She was admitted to our hospital because of persistent @entity3556 and exacerbation of @entity417 . A contrast-enhanced computed tomography scan revealed marked dilation of not only the inferior mesenteric vein, but also the left ovarian vein, the uterine vein and the internal iliac vein. A celiac arteriography showed that the blood in the splenic vein was flowing almost totally hepatofugally into the dilated inferior mesenteric vein. An ovarian venography demonstrated knob-shaped dilation of the left ovarian vein draining into the left internal iliac vein. A proximally wedged left ovarian venography visualized the right ovarian vein and the right internal iliac vein with contrast medium via a palisade venous plexus from the dilated uterine and ovarian veins. @entity887 ( @entity887 ) was performed to increase platelet count and to reduce splenic venous blood flow into the ovarian vein. Following the @entity887 , the platelet count increased, and the blood flow in the dilated ovarian vein and uterine vein diminished. In addition, the portal blood flow became hepatopetal, and remarkably increased. There has as yet been no case report in which @entity3556 developed in @entity1 with @entity1575 without any past history of hysterectomy or other @entity13374 . The present case report may be warranted in view of the rarity of the condition.

title: @entity3556 in a @entity1 with XXXX without a past history of laparotomy: successful treatment with partial splenic artery embolization.

answer: @entity1575 :: (MESH:D008103,Disease) :: ['type C liver cirrhosis']


abstract: A 47-year-old female @entity1 with @entity1575 underwent endoscopic injection sclerotherapy for esophageal varices 13  years ago. The @entity1 had no past history of hysterectomy or any other @entity13374 . She was admitted to our hospital because of persistent @entity3556 and exacerbation of @entity417 . A contrast-enhanced computed tomography scan revealed marked dilation of not only the inferior mesenteric vein, but also the left ovarian vein, the uterine vein and the internal iliac vein. A celiac arteriography showed that the blood in the splenic vein was flowing almost totally hepatofugally into the dilated inferior mesenteric vein. An ovarian venography demonstrated knob-shaped dilation of the left ovarian vein draining into the left internal iliac vein. A proximally wedged left ovarian venography visualized the right ovarian vein and the right internal iliac vein with contrast medium via a palisade venous plexus from the dilated uterine and ovarian veins. @entity887 ( @entity887 ) was performed to increase platelet count and to reduce splenic venous blood flow into the ovarian vein. Following the @entity887 , the platelet count increased, and the blood flow in the dilated ovarian vein and uterine vein diminished. In addition, the portal blood flow became hepatopetal, and remarkably increased. There has as yet been no case report in which @entity3556 developed in @entity1 with @entity1575 without any past history of hysterectomy or other @entity13374 . The present case report may be warranted in view of the rarity of the condition.

title: @entity3556 in a XXXX with @entity1575 without a past history of laparotomy: successful treatment with partial splenic artery embolization.

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: PURPOSE: To explore @entity64 survivors' perspectives of two novel models of inpatient physiotherapy, which provide an increased amount of therapy: five days a week circuit class therapy and seven days a week individual therapy. METHOD: This is a qualitative descriptive study using semi-structured interviews and thematic analysis. The @entity1 were 10 purposively sampled @entity64 survivors in the post-acute phase of recovery, who had experienced seven days a week individual therapy or five days a week circuit group therapy during inpatient rehabilitation. RESULTS: Three main themes emerged from the data: Too much, too little or just right; My experience - alone and together; and Meeting my needs. Findings revealed considerable variety in @entity1 ' beliefs, priorities and preferences regarding how intensely they could work; their experience of success and challenge individually and collectively; and their need to have their own unique individual needs met. Lack of choice seemed to be a linking concept between the themes. CONCLUSION: In order to provide @entity1 -centred services, novel methods of increased therapy must take into consideration the individual needs and preferences of the @entity1 accessing them. One model may not meet all these needs, hence a "menu" of options for therapy sessions (different timing, frequency, duration, content, rest and supervision) may be required to accommodate the diversity of @entity1 needs, preferences and capacities. Implications for Rehabilitation @entity1 with @entity64 have diverse needs and preferences regarding the modes of delivering more therapy during rehabilitation. These diverse needs may not be met by one rigid service model. Therapists and service providers could engage their clients in a dialogue about the need for more therapy and how it can be delivered. This dialogue could include options of the various ways to increase their therapy. Therapists need to provide clear reasons and education around therapy components, including rest time and practice schedules.

title: XXXX survivors' perspectives on two novel models of inpatient rehabilitation: seven-day a week individual therapy or five-day a week circuit class therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patient', 'people', 'People']

answer: @entity64 :: (MESH:D020521,Disease) :: ['Stroke']


abstract: UNASSIGNED: Tooth @entity5451 and @entity5 are two totally different diseases occurring at different ages. In the past ten years, more and more evidences suggested there was a relationship between them. High prevalence of breast, @entity694 was observed in tooth @entity5451 @entity1 . But it is still controversial. Therefore, to have a greater understanding of the possible association, a critical review on molecular association for genes involving tooth @entity5451 and tumorigenesis is necessary. In this current review, we summarized the reported cases of tooth @entity5451 with different kinds of @entity5 and the molecular relationship between these two diseases through causative genes. The results indicated tooth @entity5451 might be a prospective predictive marker for @entity5 . Through this review, we want to draw more attention on this topic and hope it will be an effective way to predict the risk of @entity5 . This article is protected by copyright. All rights reserved.

title: Hypodontia, a prospective predictive marker for XXXX ?

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon, lung and ovary tumor']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: BACKGROUND AND AIM OF THE STUDY: @entity730 ( @entity730 ) represents a significant challenge in mitral valve (MV) surgery. Techniques to decalcify the mitral annulus significantly increase operative complexity and risk. MV repair can be particularly difficult in this setting. Mid-term outcomes following MV surgery with extensive @entity8704 were examined, with attention focused on the feasibility and outcomes of MV repair in this setting. METHODS: Among 1,485 @entity1 undergoing MV surgery between 1999 and 2008 at the authors' institutions, 24 (1.6%) underwent complete posterior MV @entity8704 associated with either MV repair (n = 19) or replacement (n = 5). Extensive @entity8704 was performed from commissure to commissure in all @entity1 . The annulus was reconstructed with pledgeted compression sutures in 17 @entity1 , and with a @entity291 pericardial patch in seven. RESULTS: In-hospital mortality was 12.5%. One @entity1 died in the operating room from @entity397 , and two @entity1 died from low cardiac output postoperatively. During a mean follow up of 4.4    2.7 years, eight @entity1 died; five of these deaths were cardiovascular in nature. After five years the actuarial survival was 56    11%, and freedom from @entity204 63    11%. Four @entity1 underwent' reoperation because of failure of MV repair (n = 2), @entity884 (n = 1) or @entity2142 (n = 1). All survivors were in NYHA class  <= 2, with none to trivial @entity339 in all MV repairs. The five-year freedom from MV reoperation was 82    8%. CONCLUSION: After aggressive @entity8704 of the posterior MV annulus, both MV repair and replacement were feasible, with acceptable procedure-related mortality. It was clear however, that @entity8704 increased both complexity and risk. In well-selected @entity1 , an aggressive approach to MV repair might facilitate a high rate of repair with acceptable midterm outcome in this @entity1 population.

title: Mitral Valve Repair is Feasible Following Extensive XXXX and Reconstruction of the Atrioventricular Groove.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral regurgitation']

entities_list: @entity8704 :: ('MESH:D003649', 'Disease') :: ['decalcification', 'annular decalcification']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['MAC', 'Mitral annular calcification']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['atrioventricular groove rupture']

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['endocarditis']

answer: @entity8704 :: (MESH:D003649,Disease) :: ['Decalcification']


abstract: OBJECTIVE: We sought to compare the skin microbiota above and below the panniculus of third-trimester pregnant @entity1 with @entity28 . METHODS: We collected swabs from the anterior panniculus and from the intertriginous area under the panniculus of @entity1 with @entity28 (body mass index   >= 40 kg/m(2)) carrying a live singleton at   >= 28 weeks. DNA was extracted. PCR with primers targeting the 16S rDNA V4 region were used to prepare an amplicon library. PCR products were sequenced (Illumina MiSeq platform). The 16S rDNA sequences were processed, integrated, analyzed and reported using QIIME and in-house developed scripts. Taxonomy was assigned using RDP Classifier (threshold 0.8) against the Greengenes 16S rDNA database. RESULTS: Twenty @entity1 were enrolled. One sample pair was excluded for low sequence depth. Using permutation testing, there was significantly less bacterial diversity in the samples above compared to below the panniculus (beta diversity using weighted UniFrac metrics; p   <   0.001). CONCLUSION: In pregnant @entity1 with @entity28 , the skin microbiota in the subpannicular fold differs from and is more diverse than that on the anterior panniculus.

title: Gravidas with XXXX : evaluating the abdominal skin microbiota above and below the panniculus.

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['class III obesity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['class III obesity']


abstract: BACKGROUND: @entity882 has been frequently observed in @entity3965 @entity311 in different studies. Finding out the severity of @entity882 --is perhaps equally important, as it has practical as well as prognostic implications. The objective of the study was to assess the severity of @entity882 in @entity1 suffering, from @entity311 caused by @entity3965 . METHODS: This cross-sectional study was carried out at Combined Military Hospital (CMH) Malir, Karachi, which is a tertiary care Hospital for all military personnel _ their families in the province of Sindh. All @entity1 of smear positive Vivax malariaduring the study period were, included, and those having @entity882 from any other reason were excluded. They were treated with antimalarial drugs and their platelet counts were monitored till they normalized and discharged from the hospital. Thrombobytopenia was defined as platelets count of <150,000/cu mm. Results were. analysed by SPSS 11. RESULTS: Out of 150 cases, 133 (88%) had @entity882 . Their ages ranged from 15 to 55; mean age was 35 with SD +/- 20. Low platelet count observed was between 11,000 and 146,000/cu mm with SD +/- 27404. Mean value was 79,832/cu mm. None of the @entity1 had any @entity548 episode requiring a blood transfusion. CONCLUSION: @entity3965 associated @entity882 has a benign outcome. irrespective of severity of the platelet counts.

title: SEVERITY OF THROMBOCYTOPENIA IN @entity1 WITH XXXX MALARIA; A SINGLE CENTER STUDY.

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenia', 'thrombocytopenia']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity3965 :: ('5855', 'Species') :: ['plasmodium vivax', 'Plasmodium vivax']

answer: @entity3965 :: (5855,Species) :: ['PLASMODIUM VIVAX']


abstract: BACKGROUND: @entity882 has been frequently observed in @entity3965 @entity311 in different studies. Finding out the severity of @entity882 --is perhaps equally important, as it has practical as well as prognostic implications. The objective of the study was to assess the severity of @entity882 in @entity1 suffering, from @entity311 caused by @entity3965 . METHODS: This cross-sectional study was carried out at Combined Military Hospital (CMH) Malir, Karachi, which is a tertiary care Hospital for all military personnel _ their families in the province of Sindh. All @entity1 of smear positive Vivax malariaduring the study period were, included, and those having @entity882 from any other reason were excluded. They were treated with antimalarial drugs and their platelet counts were monitored till they normalized and discharged from the hospital. Thrombobytopenia was defined as platelets count of <150,000/cu mm. Results were. analysed by SPSS 11. RESULTS: Out of 150 cases, 133 (88%) had @entity882 . Their ages ranged from 15 to 55; mean age was 35 with SD +/- 20. Low platelet count observed was between 11,000 and 146,000/cu mm with SD +/- 27404. Mean value was 79,832/cu mm. None of the @entity1 had any @entity548 episode requiring a blood transfusion. CONCLUSION: @entity3965 associated @entity882 has a benign outcome. irrespective of severity of the platelet counts.

title: SEVERITY OF THROMBOCYTOPENIA IN XXXX WITH @entity3965 MALARIA; A SINGLE CENTER STUDY.

answer: @entity1 :: (9606,Species) :: ['PATIENTS']


abstract: UNASSIGNED: Aqueous solutions of oxalato- and citrato-VO(2+) complexes are prepared, and their ligand exchange reaction is investigated as a function of the amount of @entity1792 present in the aqueous solution via continuous-wave electron paramagnetic resonance (CW EPR) and hyperfine sublevel correlation (HYSCORE) spectroscopy. With a low amount of @entity1792 , monomeric cis-oxalato-VO(2+) complexes occur with a distorted square-pyramidal geometry. As the amount of @entity1792 increases, oxalate is gradually exchanged for @entity1792 . This leads to (i) an intermediate situation of monomeric @entity4962 complexes with a mix of oxalate/ @entity1792 ligands and (ii) a final situation of both monomeric and dimeric complexes with exclusively citrato ligands. The monomeric citrato-VO(2+) complexes dominate (abundance > 80%) and are characterized by a 6-fold chelation of the vanadium(IV) ion by 4 RCO2(-) ligands at the equatorial positions and a H2O/R-OH ligand at the axial position. The different redox stabilities of these complexes, relative to that of dissolved O2 in the aqueous solution, is analyzed via (51)V NMR. It is shown that the oxidation rate is the highest for the oxalato-VO(2+) complexes. In addition, the stability of the @entity4962 complexes can be drastically improved by evacuation of the dissolved O2 from the solution and subsequent storage in a N2 ambient atmosphere. The @entity46715 phase formation process, starting with the chemical solution deposition of the aqueous solutions and continuing with subsequent processing in an ambient 0.1% O2 atmosphere, differs for the two complexes. The oxalato-VO(2+) complexes turn into the @entity26 -deficient crystalline VO2 B at 400   C, which then turns into crystalline V6O13 at 500   C. In contrast, the citrato-VO(2+) complexes form an amorphous film at 400   C that crystallizes into VO2 M1 and V6O13 at 500   C.

title: Chemical Composition of an Aqueous Oxalato-/Citrato-VO(2+) Solution as Determinant for XXXX Phase Formation.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity46715 :: ('CHEBI:35174', 'Chemical') :: ['vanadium oxide']

answer: @entity46715 :: (CHEBI:35174,Chemical) :: ['Vanadium Oxide']


abstract: A 68-year-old @entity1 presented complaining of 2  months vague abdominal fullness and @entity1142 . She had a history of surgery 5  years ago for @entity1137 of the left breast. She had good appetite without any severe symptoms such as @entity391 , @entity294 , or @entity360 . No abnormal subcutaneous lymph nodes were detected, and blood tests showed no abnormalities including serum @entity5 markers. Whole-body computed tomography and bone scintigraphy revealed no @entity5 recurrences. However, endoscopic findings demonstrated a smooth @entity75 with submucosal thickening in the transverse colon, but the @entity694 was grossly normal. The 3-cm-long @entity75 was confirmed by colon imaging using water-soluble contrast medium. A biopsy specimen revealed diffuse infiltration of noncohesive malignant cells with round, atypical nuclei from lamina propria to subserosa. Taken together with immunohistochemistry, a diagnosis of metastatic @entity1137 from the breast was made, and transverse segmentectomy was done. Colonic @entity3 of @entity0 should be included as a differential diagnosis of any abdominal symptoms, even though mild, when @entity1 have a present or previous history of @entity0 .

title: Scirrhous colonic XXXX from @entity1137 of breast.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients']

entities_list: @entity1137 :: ('MESH:D018275', 'Disease') :: ['lobular carcinoma', 'invasive lobular carcinoma']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['stenotic lesion']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic mucous membrane']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['hematochezia']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']


abstract: A 68-year-old @entity1 presented complaining of 2  months vague abdominal fullness and @entity1142 . She had a history of surgery 5  years ago for @entity1137 of the left breast. She had good appetite without any severe symptoms such as @entity391 , @entity294 , or @entity360 . No abnormal subcutaneous lymph nodes were detected, and blood tests showed no abnormalities including serum @entity5 markers. Whole-body computed tomography and bone scintigraphy revealed no @entity5 recurrences. However, endoscopic findings demonstrated a smooth @entity75 with submucosal thickening in the transverse colon, but the @entity694 was grossly normal. The 3-cm-long @entity75 was confirmed by colon imaging using water-soluble contrast medium. A biopsy specimen revealed diffuse infiltration of noncohesive malignant cells with round, atypical nuclei from lamina propria to subserosa. Taken together with immunohistochemistry, a diagnosis of metastatic @entity1137 from the breast was made, and transverse segmentectomy was done. Colonic @entity3 of @entity0 should be included as a differential diagnosis of any abdominal symptoms, even though mild, when @entity1 have a present or previous history of @entity0 .

title: Scirrhous colonic @entity3 from XXXX of breast.

answer: @entity1137 :: (MESH:D018275,Disease) :: ['lobular carcinoma']


abstract: OBJECTIVE: Prior research has documented favorable effects of active and educational videogames among adolescents. However, research on potential negative effects of such games is limited. Scholars have called attention to games portraying sexualized female characters. The purpose of the current study was to experimentally investigate the effect of playing a videogame with a sexualized female character on adolescents' acceptance of rape myths and tolerance for @entity458 . MATERIALS AND METHODS: Fifty-seven secondary school pupils, 12-15 years of age, participated in a 2 (gender: @entity1 versus @entity1 )*2 (game character: nonsexualized versus sexualized female) factorial design experiment. @entity1 played a game for 15 minutes and were randomly assigned to one of the two game characters. Afterward, they completed established scales to assess rape myth acceptance and tolerance for @entity458 . RESULTS: Analyses of variance showed greater acceptance of rape myths (P=0.039) and greater tolerance of @entity458 (P=0.046) in adolescents who played with the sexualized @entity1 compared with adolescents in the control condition. We did not find significant differences between @entity1 and @entity1 or any interaction effect between gender and game character. CONCLUSIONS: Findings suggest that gameplaying with a sexualized @entity1 may increase adolescents' acceptance of rape myths and tolerance for @entity458 . These findings highlight attention to the use of sexualized female game characters in (educational and active) videogames that target adolescents.

title: Playing a Videogame with a Sexualized Female Character Increases Adolescents' Rape Myth Acceptance and Tolerance Toward XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'boys', 'Participants', 'girls']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual harassment']

answer: @entity458 :: (MESH:D020018,Disease) :: ['Sexual Harassment']


abstract: BACKGROUND: @entity842 (NO) has been largely associated with cardiovascular protection through improvement of endothelial function. Recently, new evidence about modulation of NO release by microRNAs (miRs) has been reported, which could be involved with statin-dependent pleiotropic effects, including anti-inflammatory properties related to vascular endothelium function. OBJECTIVE: To evaluate the effects of @entity165 -lowering drugs including the inhibitors of @entity165 synthesis, @entity2993 and @entity3413 , and the inhibitor of @entity165 absorption @entity3709 on NO release, @entity9554 mRNA expression and miRs potentially involved in NO bioavailability. METHODS: @entity1 umbilical vein endothelial cells (HUVEC) were exposed to @entity2993 , @entity3413 or @entity3709 (0 to 5.0  M). Cells were submitted to total RNA extraction and relative quantification of @entity9554 mRNA and miRs -221, -222 and -1303 by qPCR. NO release was measured in supernatants by @entity1787 -chemiluminescence. RESULTS: Both @entity6817 increased NO levels and @entity9554 mRNA expression but no influence was observed for @entity3709 treatment. @entity2993 , @entity3413 and @entity3709 down-regulated the expression of @entity494 , whereas @entity10074 was reduced only after the @entity2993 treatment. The magnitude of the reduction of @entity494 and @entity10074 after treatment with @entity6817 correlated with the increment in @entity9554 mRNA levels. No influence was observed on the miR-1303 expression after treatments. CONCLUSION: NO release in endothelial cells is increased by @entity6817 but not by the inhibitor of @entity165 absorption, @entity3709 . Our results provide new evidence about the participation of regulatory miRs 221/222 on NO release induction mediated by @entity6817 . Although @entity3709 did not modulate NO levels, the down-regulation of @entity494 could involve potential effects on endothelial function.

title: Role of microRNAs 221/222 on @entity6817 Induced XXXX Release in @entity1 Endothelial Cells.

entities_list: @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin']

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin', 'Atorvastatin']

entities_list: @entity3709 :: ('MESH:C108606', 'Chemical') :: ['ezetimibe']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity842 :: (MESH:D009569,Chemical) :: ['Nitric Oxide']


abstract: BACKGROUND: @entity842 (NO) has been largely associated with cardiovascular protection through improvement of endothelial function. Recently, new evidence about modulation of NO release by microRNAs (miRs) has been reported, which could be involved with statin-dependent pleiotropic effects, including anti-inflammatory properties related to vascular endothelium function. OBJECTIVE: To evaluate the effects of @entity165 -lowering drugs including the inhibitors of @entity165 synthesis, @entity2993 and @entity3413 , and the inhibitor of @entity165 absorption @entity3709 on NO release, @entity9554 mRNA expression and miRs potentially involved in NO bioavailability. METHODS: @entity1 umbilical vein endothelial cells (HUVEC) were exposed to @entity2993 , @entity3413 or @entity3709 (0 to 5.0  M). Cells were submitted to total RNA extraction and relative quantification of @entity9554 mRNA and miRs -221, -222 and -1303 by qPCR. NO release was measured in supernatants by @entity1787 -chemiluminescence. RESULTS: Both @entity6817 increased NO levels and @entity9554 mRNA expression but no influence was observed for @entity3709 treatment. @entity2993 , @entity3413 and @entity3709 down-regulated the expression of @entity494 , whereas @entity10074 was reduced only after the @entity2993 treatment. The magnitude of the reduction of @entity494 and @entity10074 after treatment with @entity6817 correlated with the increment in @entity9554 mRNA levels. No influence was observed on the miR-1303 expression after treatments. CONCLUSION: NO release in endothelial cells is increased by @entity6817 but not by the inhibitor of @entity165 absorption, @entity3709 . Our results provide new evidence about the participation of regulatory miRs 221/222 on NO release induction mediated by @entity6817 . Although @entity3709 did not modulate NO levels, the down-regulation of @entity494 could involve potential effects on endothelial function.

title: Role of microRNAs 221/222 on XXXX Induced @entity842 Release in @entity1 Endothelial Cells.

answer: @entity6817 :: (D019821,Chemical) :: ['Statin']


abstract: BACKGROUND: @entity842 (NO) has been largely associated with cardiovascular protection through improvement of endothelial function. Recently, new evidence about modulation of NO release by microRNAs (miRs) has been reported, which could be involved with statin-dependent pleiotropic effects, including anti-inflammatory properties related to vascular endothelium function. OBJECTIVE: To evaluate the effects of @entity165 -lowering drugs including the inhibitors of @entity165 synthesis, @entity2993 and @entity3413 , and the inhibitor of @entity165 absorption @entity3709 on NO release, @entity9554 mRNA expression and miRs potentially involved in NO bioavailability. METHODS: @entity1 umbilical vein endothelial cells (HUVEC) were exposed to @entity2993 , @entity3413 or @entity3709 (0 to 5.0  M). Cells were submitted to total RNA extraction and relative quantification of @entity9554 mRNA and miRs -221, -222 and -1303 by qPCR. NO release was measured in supernatants by @entity1787 -chemiluminescence. RESULTS: Both @entity6817 increased NO levels and @entity9554 mRNA expression but no influence was observed for @entity3709 treatment. @entity2993 , @entity3413 and @entity3709 down-regulated the expression of @entity494 , whereas @entity10074 was reduced only after the @entity2993 treatment. The magnitude of the reduction of @entity494 and @entity10074 after treatment with @entity6817 correlated with the increment in @entity9554 mRNA levels. No influence was observed on the miR-1303 expression after treatments. CONCLUSION: NO release in endothelial cells is increased by @entity6817 but not by the inhibitor of @entity165 absorption, @entity3709 . Our results provide new evidence about the participation of regulatory miRs 221/222 on NO release induction mediated by @entity6817 . Although @entity3709 did not modulate NO levels, the down-regulation of @entity494 could involve potential effects on endothelial function.

title: Role of microRNAs 221/222 on @entity6817 Induced @entity842 Release in XXXX Endothelial Cells.

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: PURPOSE: To compare the rates of success of two-dimensional (2D) and three-dimensional (3D) sonographic (US) examinations in locating and adequately visualizing @entity2692 intrauterine devices (IUDs) and to explore factors associated with the unsuccessful viewing on 2D US. METHODS: Transvaginal 2D and 3D US examinations were performed on all @entity1 1 month after insertion of @entity2692 IUDs. The devices were considered adequately visualized on 2D US if both the vertical (shadow, upper and lower extremities) and the horizontal (two echogenic lines) shafts were identified. 3D volumes were also captured to assess the location of @entity2692 IUDs on 3D US. RESULTS: Thirty @entity1 were included. The rates of adequate device visualization were 40% on 2D US (95% confidence interval [CI], 24.6; 57.7) and 100% on 3D US (95% CI, 88.6; 100.0). The device was not adequately visualized in all six @entity1 who had a retroflexed uterus, but it was adequately visualized in 12 of the 24 @entity1 (50%) who had a nonretroflexed uterus (95% CI, -68.6; -6.8). CONCLUSIONS: We found that 3D US is better than 2D US for locating and adequately visualizing @entity2692 IUDs. Other well-designed studies with adequate power should be conducted to confirm this finding.    2015 Wiley Periodicals, Inc. J Clin Ultrasound, 2015.

title: Three-dimensional versus two-dimensional ultrasound for assessing XXXX intrauterine device location: A pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'women']

entities_list: @entity2692 :: ('MESH:D016912', 'Chemical') :: ['levonorgestrel']

answer: @entity2692 :: (MESH:D016912,Chemical) :: ['levonorgestrel']


abstract: BACKGROUND: By the early nineteenth century, @entity0 was better understood and surgical treatment was emerging as a more favoured option although anaesthesia had yet to be discovered. Many questions would have arisen for a @entity1 advised to have surgery, including possible alternatives, what the operation would entail, @entity158 and risks involved and the competence, ethical and professional behaviour of the surgeon. This paper addresses these questions in the context of the contemporary environment, focusing in particular on the personal experiences of the @entity1 involved. METHODS: A review of the surviving personal letters and information regarding three @entity1 who had breast surgery, and of the contemporary surgical writings on @entity0 , training of surgeons, ethical and professional expectations and the concurrent status of @entity1 in society. RESULTS: Surgical training was in its infancy and the first pronouncements on medical ethics had just been published. @entity158 , @entity548 and @entity281 presented formidable challenges and carried significant risks. @entity1 were frequently devoid of information, suffered a loss of their dignity and were progressively stripped of their authority. CONCLUSIONS: @entity0 surgery was accompanied by enormous emotional and physical distress and significant risks from @entity548 and @entity281 . Although efforts were being made to give @entity1 a greater voice and autonomy in society, their position when receiving health care remained largely a submissive one. Lack of information, feelings of vulnerability, helplessness and loss of control occurred. The public perception of detachment most likely accounted for the occasional negative stigma then associated with the surgical profession.

title: Mastectomy with tears: XXXX surgery in the early nineteenth century.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'Women']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: To describe the etiologies, clinical presentations, outcomes, and predictors of @entity302 ( @entity302 ) in a large series of adult @entity1 with acute @entity198 . METHODS: We conducted a retrospective review of @entity1 diagnosed with acute @entity198 at Mayo Clinic, Rochester, between January 2000 and December 2012. The @entity1 were categorized into two groups based on the presence or absence of @entity302 at last follow-up. Multivariate logistic regression analysis was used to analyze factors associated with @entity302 . RESULTS: We identified 198 consecutive @entity1 (100 [50.5%] male and 98 [49.5%] female) with a median age of 58  years (range 41.8-69). Etiologies included @entity1800 (n  =  95, 48%), autoimmune (n  =  44, 22%), and unknown/others (n  =  59, 30%). During hospitalization, @entity410 were seen in @entity1 with @entity14752 (n  =  24, 54.5%), unknown/others (n  =  20, 33.9%), and @entity11410 (n  =  23, 24.2%). Interictal epileptiform discharges on electroencephalography (EEG) were present in 34 (54%), whereas periodic lateralized epileptiform discharges (PLEDs) and generalized periodic discharges (GPDs) were seen in 14 (41.2%) and 2 (5.9%) @entity1 . Forty-six @entity1 with @entity410 (70.8%) had fluid-attenuated inversion recovery (FLAIR)/T2 abnormalities, 20 (31.3%) diffusion abnormalities, and 43 (66.2%) cortical involvement. Good outcome at discharge among @entity1 with @entity410 was seen in 8/23 @entity1 with viral etiology (34.8%), 10/24 @entity1 with @entity14752 (45.5%), and 12/20 @entity1 with unknown cause (60%). @entity302 was present in 43 @entity1 (29.9%). On multivariate regression analysis, the factors associated with @entity302 were generalized @entity410 during hospitalization (p  =  0.03), focal @entity410 (p   <=  0.001), and the presence of FLAIR/T2 abnormalities on brain magnetic resonance imaging (MRI) (p  =  0.003). SIGNIFICANCE: The presence of @entity410 during hospitalization and an abnormal brain MRI are the strongest predictors of the development of @entity302 . The etiology of @entity198 , presence of focal @entity51 , and interictal EEG abnormalities did not influence the development of @entity302 .

title: XXXX : Clinical characteristics and predictors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis']

entities_list: @entity11410 :: ('MESH:D018792', 'Disease') :: ['viral encephalitis']

entities_list: @entity14752 :: ('MESH:C535841', 'Disease') :: ['autoimmune encephalitis']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infection']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficits']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['postencephalitic epilepsy', 'PE']

answer: @entity302 :: (MESH:D004827,Disease) :: ['Postencephalitic epilepsy']


abstract: OBJECTIVE: To perform a meta-analysis of studies investigating the effects of low-frequency repetitive transcranial magnetic stimulation on post- @entity64 @entity2026 . DATA SOURCES: Studies were identified by performing a search of electronic databases (MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Knowledge) for articles published until June 2014. STUDY SELECTION: @entity23 ( @entity23 ) reporting treatments with low-frequency repetitive transcranial magnetic stimulation in @entity1 with post- @entity64 @entity2026 were included. The outcomes included naming, repetition, comprehension, changes in brain excitability, and adverse events. DATA EXTRACTION: Two independent reviewers extracted the data. Study quality was evaluated with the PEDro scale. DATA ANALYSIS: Of the 879 articles identified, 4 @entity23 were included in the final analysis. Data synthesis showed that low-frequency repetitive transcranial magnetic stimulation was beneficial for post- @entity64 @entity1 in terms of naming (standard mean difference (SMD) 0.51; 95% confidence interval (95% CI) 0.16-0.86) and changes in brain excitability (7.6        33.55; 95% CI -10.7-26.20). However, the changes in repetition (SMD 0.31; 95% CI -0.04-0.65) and comprehension (SMD 0.31; 95% CI -0.14-0.75) after stimulation were not significant. No adverse effects were reported. The included studies were of high methodological quality. CONCLUSION: These findings indicate that low-frequency repetitive transcranial magnetic stimulation is an effective treatment for recovery of naming. In addition, this treatment favours reorganization of the left-hemispheric language networks.

title: Low-frequency repetitive transcranial magnetic stimulation for @entity1 with XXXX after stoke: A meta-analysis.

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['Randomized controlled trials', 'RCTs']

answer: @entity2026 :: (MESH:D001037,Disease) :: ['aphasia']


abstract: OBJECTIVE: To perform a meta-analysis of studies investigating the effects of low-frequency repetitive transcranial magnetic stimulation on post- @entity64 @entity2026 . DATA SOURCES: Studies were identified by performing a search of electronic databases (MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Knowledge) for articles published until June 2014. STUDY SELECTION: @entity23 ( @entity23 ) reporting treatments with low-frequency repetitive transcranial magnetic stimulation in @entity1 with post- @entity64 @entity2026 were included. The outcomes included naming, repetition, comprehension, changes in brain excitability, and adverse events. DATA EXTRACTION: Two independent reviewers extracted the data. Study quality was evaluated with the PEDro scale. DATA ANALYSIS: Of the 879 articles identified, 4 @entity23 were included in the final analysis. Data synthesis showed that low-frequency repetitive transcranial magnetic stimulation was beneficial for post- @entity64 @entity1 in terms of naming (standard mean difference (SMD) 0.51; 95% confidence interval (95% CI) 0.16-0.86) and changes in brain excitability (7.6        33.55; 95% CI -10.7-26.20). However, the changes in repetition (SMD 0.31; 95% CI -0.04-0.65) and comprehension (SMD 0.31; 95% CI -0.14-0.75) after stimulation were not significant. No adverse effects were reported. The included studies were of high methodological quality. CONCLUSION: These findings indicate that low-frequency repetitive transcranial magnetic stimulation is an effective treatment for recovery of naming. In addition, this treatment favours reorganization of the left-hemispheric language networks.

title: Low-frequency repetitive transcranial magnetic stimulation for XXXX with @entity2026 after stoke: A meta-analysis.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: To evaluate the refractive and keratometric effect of arcuate keratotomy using femtosecond technology in @entity1 with high post-keratoplasty @entity940 with a mushroom profile. SETTING: Enaim Refractive Center, @entity9604 -Aviv, Israel. DESIGN: Noncomparative prospective interventional case series. METHODS: The arcuate depth incision was set to 80% of the minimal graft thickness, with a 60-degree angle. The mean diameter was 5.79 mm    0.32 (SD) according to the graft size. @entity1 evaluation included logMAR corrected distance visual acuity (CDVA), refraction, keratometry (K), and a complete eye examination. RESULTS: Twenty-seven eyes of 27 @entity1 after keratoplasty surgery were included. Both uncorrected distance visual acuity and logMAR CDVA improved after surgery. The preoperative mean logMAR CDVA was 0.29    0.37 (SD), which improved by 1 line (to 0.19    0.10; P = .01). The mean refractive @entity940 was -8.43    2.80 diopters (D) (range -4.5 to -15 D), and it declined at the 3-month postsurgical follow-up to -4.31    0.23 D (P < .001) and remained stable until the end of follow-up (-3.31    1.39 D; P = 1.00). The K value decreased by 1.18 D (P  < .001). There were no complications or adverse effects during the follow-up period. CONCLUSIONS: Arcuate keratotomies performed with the femtosecond laser showed good results. There was a more than 50% decrease in post-mushroom profile keratoplasty @entity940 as well as stability of the results over 1 year. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

title: Correction ratio and vector analysis of  femtosecond laser arcuate keratotomy for  the correction of post-mushroom profile  keratoplasty XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity940 :: ('MESH:D001251', 'Disease') :: ['astigmatism']

answer: @entity940 :: (MESH:D001251,Disease) :: ['astigmatism']


abstract: UNASSIGNED: Although @entity384 is an accepted method for the treatment of @entity1318 , this therapy has high recurrence and complication rates, and prolonged follow-up studies on the parameters associated with various outcomes are rare. In this prospective 10-year follow-up study, a satisfactory therapeutic effect was achieved without serious complications. We report the therapeutic experience with @entity384 , having aimed to evaluate the long-term clinical safety and efficacy of @entity384 .In total, 35 consecutive @entity1 with idiopathic @entity1318 who underwent @entity384 were followed up at regular intervals in @entity1 or by a phone interview over a 10-year period. The mean duration of the follow-up was 43.03  26.34 months (range 6-120 months). Remission was assessed by the @entity1282 classification and symptom scores. @entity1 ' clinical symptom scores were calculated before and at 6 to 36months, 37 to 60months, and >60months after therapy. The influence of the @entity1 ' age, gender, and disease duration on the therapeutic effect was analyzed.The success rate of the operation was 97.2% (35/36), without massive @entity548 , perforation or other serious complications. @entity1282 after the therapy was significantly eased (P<0.01). In total, 35 @entity1 have been followed up for 6 to 36months after therapy, 21 cases for 37 to 60months, and 5 cases for >60months, and the @entity1 ' symptom scores separately decreased significantly compared with the pretherapy scores (P<0.01). For these @entity1 , the 6 to 36months remission rate was 85.7% (30/35), the 37 to 60months rate was 61.9% (13/21), and the >60months rate was 40% (2/5). The dilation effect had no relationship to the @entity1 's age, gender, and disease duration (P>0.05). The @entity1 in 30 cases (85.7%) were successfully treated with a single dilation, in 4 cases (11.4%) with 2 dilations, and in 1 case (2.9%) with 3 dilations.These results suggest that endoscopic @entity384 is an @entity1318 therapy with a good response; it is a simple and safe procedure with long-term clinical effectiveness. It is a preferred method in the treatment of @entity1318 .

title: Clinical Effect of Endoscopic Pneumatic Dilation for XXXX .

entities_list: @entity1318 :: ('MESH:D004931', 'Disease') :: ['achalasia']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'person']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhaging']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['pneumatic dilation']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['Dysphagia', 'dysphagia']

answer: @entity1318 :: (MESH:D004931,Disease) :: ['Achalasia']


abstract: AIM: To investigate the nature of @entity2299 and its diversity in @entity1 with @entity1582 . METHODS: The reports of the kidney biopsies performed due to @entity1985 (>3.5   g/day/1.73   m(2)) with preserved renal function [glomerular filtration rate (GFR) >60   mL/ @entity1009 .73   m(2)] were reviewed. Clinical and laboratory data of the @entity1 with @entity1582 and @entity631 ( @entity631 ) were analyzed. RESULTS: A total of 104 ( @entity1582 : 43, @entity631 : 61) @entity1 were included in the study. @entity644 and GFR levels were similar in both the groups. @entity1 with @entity1582 group had lower serum albumin (p   =   0.002), lower hemoglobin levels (p   =   0.001), higher platelet counts (p   =   0.002) and higher @entity1851 levels (p   =   0.001) compared to @entity1 in @entity631 group. Although the frequency of @entity2299 was similar in the groups (86.0 vs. 93.4%), @entity1 with @entity1582 had both lower values of LDL-C (4.56        2.05 vs. 5.49        2.23   mmol/L, p   =   0.028) and HDL-C (1.19        0.36 vs. 1.35        0.39   mmol/L, p   =   0.035). Serum lipid levels were correlated with serum total protein, albumin and @entity644 levels in @entity631 group. However, in the @entity1582 group, only one clear correlation between serum lipid and hemoglobin levels was estimated. A multivariate analysis demonstrated that LDL-C was independently associated with the etiology of @entity1985 , serum total protein, serum albumin (inversely) and hemoglobin levels. CONCLUSIONS: Although @entity2299 is closely associated with serum total protein, albumin and @entity644 in @entity1 with @entity631 , there is no clear such association in @entity1 with @entity1582 . Correlation between serum lipid and hemoglobin levels in this group and other findings point out that probably complex mechanisms take place in @entity2299 of @entity1985 caused by @entity1582 .

title: Unknown aspect of the old disease: does @entity2299 in @entity1582 in XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria', 'Proteinuria']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['systemic AA amyloidosis', 'systemic amyloidosis']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic proteinuria', 'nephrotic syndrome']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['PG', 'primary glomerulonephritis']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity631 :: (MESH:D005921,Disease) :: ['primary glomerulonephritis']


abstract: AIM: To investigate the nature of @entity2299 and its diversity in @entity1 with @entity1582 . METHODS: The reports of the kidney biopsies performed due to @entity1985 (>3.5   g/day/1.73   m(2)) with preserved renal function [glomerular filtration rate (GFR) >60   mL/ @entity1009 .73   m(2)] were reviewed. Clinical and laboratory data of the @entity1 with @entity1582 and @entity631 ( @entity631 ) were analyzed. RESULTS: A total of 104 ( @entity1582 : 43, @entity631 : 61) @entity1 were included in the study. @entity644 and GFR levels were similar in both the groups. @entity1 with @entity1582 group had lower serum albumin (p   =   0.002), lower hemoglobin levels (p   =   0.001), higher platelet counts (p   =   0.002) and higher @entity1851 levels (p   =   0.001) compared to @entity1 in @entity631 group. Although the frequency of @entity2299 was similar in the groups (86.0 vs. 93.4%), @entity1 with @entity1582 had both lower values of LDL-C (4.56        2.05 vs. 5.49        2.23   mmol/L, p   =   0.028) and HDL-C (1.19        0.36 vs. 1.35        0.39   mmol/L, p   =   0.035). Serum lipid levels were correlated with serum total protein, albumin and @entity644 levels in @entity631 group. However, in the @entity1582 group, only one clear correlation between serum lipid and hemoglobin levels was estimated. A multivariate analysis demonstrated that LDL-C was independently associated with the etiology of @entity1985 , serum total protein, serum albumin (inversely) and hemoglobin levels. CONCLUSIONS: Although @entity2299 is closely associated with serum total protein, albumin and @entity644 in @entity1 with @entity631 , there is no clear such association in @entity1 with @entity1582 . Correlation between serum lipid and hemoglobin levels in this group and other findings point out that probably complex mechanisms take place in @entity2299 of @entity1985 caused by @entity1582 .

title: Unknown aspect of the old disease: does XXXX in @entity1582 in @entity631 ?

answer: @entity2299 :: (MESH:D050171,Disease) :: ['dyslipidemia']


abstract: AIM: To investigate the nature of @entity2299 and its diversity in @entity1 with @entity1582 . METHODS: The reports of the kidney biopsies performed due to @entity1985 (>3.5   g/day/1.73   m(2)) with preserved renal function [glomerular filtration rate (GFR) >60   mL/ @entity1009 .73   m(2)] were reviewed. Clinical and laboratory data of the @entity1 with @entity1582 and @entity631 ( @entity631 ) were analyzed. RESULTS: A total of 104 ( @entity1582 : 43, @entity631 : 61) @entity1 were included in the study. @entity644 and GFR levels were similar in both the groups. @entity1 with @entity1582 group had lower serum albumin (p   =   0.002), lower hemoglobin levels (p   =   0.001), higher platelet counts (p   =   0.002) and higher @entity1851 levels (p   =   0.001) compared to @entity1 in @entity631 group. Although the frequency of @entity2299 was similar in the groups (86.0 vs. 93.4%), @entity1 with @entity1582 had both lower values of LDL-C (4.56        2.05 vs. 5.49        2.23   mmol/L, p   =   0.028) and HDL-C (1.19        0.36 vs. 1.35        0.39   mmol/L, p   =   0.035). Serum lipid levels were correlated with serum total protein, albumin and @entity644 levels in @entity631 group. However, in the @entity1582 group, only one clear correlation between serum lipid and hemoglobin levels was estimated. A multivariate analysis demonstrated that LDL-C was independently associated with the etiology of @entity1985 , serum total protein, serum albumin (inversely) and hemoglobin levels. CONCLUSIONS: Although @entity2299 is closely associated with serum total protein, albumin and @entity644 in @entity1 with @entity631 , there is no clear such association in @entity1 with @entity1582 . Correlation between serum lipid and hemoglobin levels in this group and other findings point out that probably complex mechanisms take place in @entity2299 of @entity1985 caused by @entity1582 .

title: Unknown aspect of the old disease: does @entity2299 in XXXX in @entity631 ?

answer: @entity1582 :: (MESH:D009101,Disease) :: ['systemic AA amyloidosis differ from the dyslipidemia']


abstract: UNASSIGNED: Although dietary @entity4613 restriction is important for treating @entity2265 in @entity1 with @entity740 , it remains unclear whether a @entity258 ( @entity258 ), which includes low @entity4613 , has beneficial effects on @entity3147 , @entity32 , and @entity729 . The effects of @entity258 on @entity32 , @entity3147 , and @entity729 were therefore assessed in @entity35 . @entity35 were fed a normal diet or diets containing 0.3% @entity5536 and low/normal protein and low/high @entity4613 . After 6 weeks, serum and urinary biochemical parameters, systemic @entity32 , and @entity729 were examined. The protective effect of @entity71791 and albumin were assessed in cultured vascular smooth muscle cells. @entity35 fed the diet containing 0.3% @entity5536 developed severe @entity2629 . @entity258 in @entity35 fed high @entity4613 induced @entity3147 (decreases in body weight, food intake, serum albumin and @entity71791 levels, and urinary @entity1011 excretion) and systemic @entity32 (increases in serum @entity5 @entity39 factor-a and urinary oxidative stress marker). @entity258 decreased serum @entity71791 level and @entity71791 synthesis in the liver and increased serum @entity78 precipitates. High @entity4613 diet increased aortic @entity460 content, which was enhanced by @entity258 . Reduced fetal calf serum in the medium of cultured vascular smooth muscle cells enhanced @entity4613 -induced formation of @entity78 precipitates in the media and calcification of vascular smooth muscle cells, both of which were prevented by @entity71791 administration. Our results suggest that @entity4613 restriction by restricting dietary protein promotes @entity729 by lowering systemic @entity71791 level and increasing serum @entity78 precipitates and induces @entity32 and @entity3147 in uremic @entity35 fed a high @entity4613 diet.

title: @entity71791 decrease induced by a @entity258 enhances XXXX in uremic @entity35 with @entity2265 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity78 :: ('MESH:C020243', 'Chemical') :: ['calcium-phosphate']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease']

entities_list: @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity729 :: ('MESH:D061205', 'Disease') :: ['vascular calcification']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['LPD', 'low protein diet']

answer: @entity729 :: (MESH:D061205,Disease) :: ['vascular calcification']


abstract: UNASSIGNED: Although dietary @entity4613 restriction is important for treating @entity2265 in @entity1 with @entity740 , it remains unclear whether a @entity258 ( @entity258 ), which includes low @entity4613 , has beneficial effects on @entity3147 , @entity32 , and @entity729 . The effects of @entity258 on @entity32 , @entity3147 , and @entity729 were therefore assessed in @entity35 . @entity35 were fed a normal diet or diets containing 0.3% @entity5536 and low/normal protein and low/high @entity4613 . After 6 weeks, serum and urinary biochemical parameters, systemic @entity32 , and @entity729 were examined. The protective effect of @entity71791 and albumin were assessed in cultured vascular smooth muscle cells. @entity35 fed the diet containing 0.3% @entity5536 developed severe @entity2629 . @entity258 in @entity35 fed high @entity4613 induced @entity3147 (decreases in body weight, food intake, serum albumin and @entity71791 levels, and urinary @entity1011 excretion) and systemic @entity32 (increases in serum @entity5 @entity39 factor-a and urinary oxidative stress marker). @entity258 decreased serum @entity71791 level and @entity71791 synthesis in the liver and increased serum @entity78 precipitates. High @entity4613 diet increased aortic @entity460 content, which was enhanced by @entity258 . Reduced fetal calf serum in the medium of cultured vascular smooth muscle cells enhanced @entity4613 -induced formation of @entity78 precipitates in the media and calcification of vascular smooth muscle cells, both of which were prevented by @entity71791 administration. Our results suggest that @entity4613 restriction by restricting dietary protein promotes @entity729 by lowering systemic @entity71791 level and increasing serum @entity78 precipitates and induces @entity32 and @entity3147 in uremic @entity35 fed a high @entity4613 diet.

title: @entity71791 decrease induced by a @entity258 enhances @entity729 in uremic XXXX with @entity2265 .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: UNASSIGNED: Although dietary @entity4613 restriction is important for treating @entity2265 in @entity1 with @entity740 , it remains unclear whether a @entity258 ( @entity258 ), which includes low @entity4613 , has beneficial effects on @entity3147 , @entity32 , and @entity729 . The effects of @entity258 on @entity32 , @entity3147 , and @entity729 were therefore assessed in @entity35 . @entity35 were fed a normal diet or diets containing 0.3% @entity5536 and low/normal protein and low/high @entity4613 . After 6 weeks, serum and urinary biochemical parameters, systemic @entity32 , and @entity729 were examined. The protective effect of @entity71791 and albumin were assessed in cultured vascular smooth muscle cells. @entity35 fed the diet containing 0.3% @entity5536 developed severe @entity2629 . @entity258 in @entity35 fed high @entity4613 induced @entity3147 (decreases in body weight, food intake, serum albumin and @entity71791 levels, and urinary @entity1011 excretion) and systemic @entity32 (increases in serum @entity5 @entity39 factor-a and urinary oxidative stress marker). @entity258 decreased serum @entity71791 level and @entity71791 synthesis in the liver and increased serum @entity78 precipitates. High @entity4613 diet increased aortic @entity460 content, which was enhanced by @entity258 . Reduced fetal calf serum in the medium of cultured vascular smooth muscle cells enhanced @entity4613 -induced formation of @entity78 precipitates in the media and calcification of vascular smooth muscle cells, both of which were prevented by @entity71791 administration. Our results suggest that @entity4613 restriction by restricting dietary protein promotes @entity729 by lowering systemic @entity71791 level and increasing serum @entity78 precipitates and induces @entity32 and @entity3147 in uremic @entity35 fed a high @entity4613 diet.

title: @entity71791 decrease induced by a @entity258 enhances @entity729 in uremic @entity35 with XXXX .

answer: @entity2265 :: (MESH:D054559,Disease) :: ['hyperphosphatemia']


abstract: UNASSIGNED: Although dietary @entity4613 restriction is important for treating @entity2265 in @entity1 with @entity740 , it remains unclear whether a @entity258 ( @entity258 ), which includes low @entity4613 , has beneficial effects on @entity3147 , @entity32 , and @entity729 . The effects of @entity258 on @entity32 , @entity3147 , and @entity729 were therefore assessed in @entity35 . @entity35 were fed a normal diet or diets containing 0.3% @entity5536 and low/normal protein and low/high @entity4613 . After 6 weeks, serum and urinary biochemical parameters, systemic @entity32 , and @entity729 were examined. The protective effect of @entity71791 and albumin were assessed in cultured vascular smooth muscle cells. @entity35 fed the diet containing 0.3% @entity5536 developed severe @entity2629 . @entity258 in @entity35 fed high @entity4613 induced @entity3147 (decreases in body weight, food intake, serum albumin and @entity71791 levels, and urinary @entity1011 excretion) and systemic @entity32 (increases in serum @entity5 @entity39 factor-a and urinary oxidative stress marker). @entity258 decreased serum @entity71791 level and @entity71791 synthesis in the liver and increased serum @entity78 precipitates. High @entity4613 diet increased aortic @entity460 content, which was enhanced by @entity258 . Reduced fetal calf serum in the medium of cultured vascular smooth muscle cells enhanced @entity4613 -induced formation of @entity78 precipitates in the media and calcification of vascular smooth muscle cells, both of which were prevented by @entity71791 administration. Our results suggest that @entity4613 restriction by restricting dietary protein promotes @entity729 by lowering systemic @entity71791 level and increasing serum @entity78 precipitates and induces @entity32 and @entity3147 in uremic @entity35 fed a high @entity4613 diet.

title: @entity71791 decrease induced by a XXXX enhances @entity729 in uremic @entity35 with @entity2265 .

answer: @entity258 :: (MESH:D009800,Disease) :: ['low protein diet']


abstract: UNASSIGNED: Although dietary @entity4613 restriction is important for treating @entity2265 in @entity1 with @entity740 , it remains unclear whether a @entity258 ( @entity258 ), which includes low @entity4613 , has beneficial effects on @entity3147 , @entity32 , and @entity729 . The effects of @entity258 on @entity32 , @entity3147 , and @entity729 were therefore assessed in @entity35 . @entity35 were fed a normal diet or diets containing 0.3% @entity5536 and low/normal protein and low/high @entity4613 . After 6 weeks, serum and urinary biochemical parameters, systemic @entity32 , and @entity729 were examined. The protective effect of @entity71791 and albumin were assessed in cultured vascular smooth muscle cells. @entity35 fed the diet containing 0.3% @entity5536 developed severe @entity2629 . @entity258 in @entity35 fed high @entity4613 induced @entity3147 (decreases in body weight, food intake, serum albumin and @entity71791 levels, and urinary @entity1011 excretion) and systemic @entity32 (increases in serum @entity5 @entity39 factor-a and urinary oxidative stress marker). @entity258 decreased serum @entity71791 level and @entity71791 synthesis in the liver and increased serum @entity78 precipitates. High @entity4613 diet increased aortic @entity460 content, which was enhanced by @entity258 . Reduced fetal calf serum in the medium of cultured vascular smooth muscle cells enhanced @entity4613 -induced formation of @entity78 precipitates in the media and calcification of vascular smooth muscle cells, both of which were prevented by @entity71791 administration. Our results suggest that @entity4613 restriction by restricting dietary protein promotes @entity729 by lowering systemic @entity71791 level and increasing serum @entity78 precipitates and induces @entity32 and @entity3147 in uremic @entity35 fed a high @entity4613 diet.

title: XXXX decrease induced by a @entity258 enhances @entity729 in uremic @entity35 with @entity2265 .

answer: @entity71791 :: (25373(Tax:10116),Gene) :: ['Fetuin-A']


abstract: The objective of present study was to formulate directly compressible orodispersible tablets of @entity1089 by sublimation method with a view to enhance @entity1 compliance. A full 3(2) factorial design was used to investigate the effect of two variables viz., concentration of Indion 414 and @entity9679 . Indion 414 (3-5 % w/w) was used as superdisintegrant and @entity9679 (5-15 % w/w) as subliming agent. The tablets were evaluated for thickness, weight variation, @entity3358 , friability, content uniformity, wetting time, porosity, in vitro disintegration time and in vitro drug release. The formulation containing 5% w/w of Indion 414 and 5% w/w @entity9679 was emerged as promising based on evaluation parameters. The disintegration time for optimized formulation was 18.66 s. The tablet surface was evaluated for presence of pores by scanning electron microscopy before and after sublimation. Differential scanning colorimetric study did not indicate any drug excipient incompatibility, either during mixing or after compression. The effect of independent variables on disintegration time, % drug release and friability is presented graphically by surface response plots. Short-term stability studies on the optimized formulation indicated no significant changes in drug content and in vitro disintegration time. The directly compressible orodispersible tablets of @entity1089 fumarate with lower friability, greater drug release and shorter disintegration times were obtained using Indion 414 and @entity9679 at optimum concentrations.

title: Formulation Design and Optimization of Orodispersible Tablets of XXXX by Sublimation Method.

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine', 'quetiapine fumarate']

answer: @entity1089 :: (MESH:C069541,Chemical) :: ['Quetiapine Fumarate']


abstract: In both the @entity1 and animal literature, it has largely been assumed that @entity4 is the primary cause of @entity428 ( @entity428 ) elevation after @entity64 and that more @entity4 equates to higher @entity428 . We recently demonstrated a dramatic @entity428 elevation 24 hours after small @entity385 in @entity35 , with minimal @entity4 . This @entity428 elevation was completely prevented by short-duration moderate @entity2332 soon after @entity64 . Here, our aims were to determine the importance of @entity4 in @entity428 elevation after @entity64 and whether mild @entity2332 could prevent the @entity428 rise. @entity64 was performed in @entity35 . @entity428 was monitored and short-duration mild (35   C) or moderate (32.5   C) @entity2332 , or normothermia (37   C) was induced after @entity64 onset. @entity4 was measured in three studies, using wet-dry weight calculations, T2-weighted magnetic resonance imaging, or histology. @entity428 increased 24 hours after @entity64 onset in all normothermic animals. Short-duration mild or moderate @entity2332 prevented this rise. No correlation was seen between   @entity428 and @entity4 or @entity1188 volumes. Calculated rates of @entity4 growth were orders of magnitude less than normal cerebrospinal fluid production rates. These data challenge current concepts and suggest that factors other than @entity2657 are the primary cause of the @entity428 elevation 24 hours after @entity64 onset.

title: Intracranial pressure elevation after @entity385 in @entity35 : XXXX is not the only cause, and short-duration mild @entity2332 is a highly effective preventive therapy.

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['Experimental stroke', 'stroke']

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['cerebral edema']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP', 'intracranial pressure']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edema', 'Edema']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic strokes']

answer: @entity2657 :: (MESH:D001929,Disease) :: ['cerebral edema']


abstract: In both the @entity1 and animal literature, it has largely been assumed that @entity4 is the primary cause of @entity428 ( @entity428 ) elevation after @entity64 and that more @entity4 equates to higher @entity428 . We recently demonstrated a dramatic @entity428 elevation 24 hours after small @entity385 in @entity35 , with minimal @entity4 . This @entity428 elevation was completely prevented by short-duration moderate @entity2332 soon after @entity64 . Here, our aims were to determine the importance of @entity4 in @entity428 elevation after @entity64 and whether mild @entity2332 could prevent the @entity428 rise. @entity64 was performed in @entity35 . @entity428 was monitored and short-duration mild (35   C) or moderate (32.5   C) @entity2332 , or normothermia (37   C) was induced after @entity64 onset. @entity4 was measured in three studies, using wet-dry weight calculations, T2-weighted magnetic resonance imaging, or histology. @entity428 increased 24 hours after @entity64 onset in all normothermic animals. Short-duration mild or moderate @entity2332 prevented this rise. No correlation was seen between   @entity428 and @entity4 or @entity1188 volumes. Calculated rates of @entity4 growth were orders of magnitude less than normal cerebrospinal fluid production rates. These data challenge current concepts and suggest that factors other than @entity2657 are the primary cause of the @entity428 elevation 24 hours after @entity64 onset.

title: Intracranial pressure elevation after @entity385 in @entity35 : @entity2657 is not the only cause, and short-duration mild XXXX is a highly effective preventive therapy.

answer: @entity2332 :: (MESH:D007035,Disease) :: ['hypothermia']


abstract: In both the @entity1 and animal literature, it has largely been assumed that @entity4 is the primary cause of @entity428 ( @entity428 ) elevation after @entity64 and that more @entity4 equates to higher @entity428 . We recently demonstrated a dramatic @entity428 elevation 24 hours after small @entity385 in @entity35 , with minimal @entity4 . This @entity428 elevation was completely prevented by short-duration moderate @entity2332 soon after @entity64 . Here, our aims were to determine the importance of @entity4 in @entity428 elevation after @entity64 and whether mild @entity2332 could prevent the @entity428 rise. @entity64 was performed in @entity35 . @entity428 was monitored and short-duration mild (35   C) or moderate (32.5   C) @entity2332 , or normothermia (37   C) was induced after @entity64 onset. @entity4 was measured in three studies, using wet-dry weight calculations, T2-weighted magnetic resonance imaging, or histology. @entity428 increased 24 hours after @entity64 onset in all normothermic animals. Short-duration mild or moderate @entity2332 prevented this rise. No correlation was seen between   @entity428 and @entity4 or @entity1188 volumes. Calculated rates of @entity4 growth were orders of magnitude less than normal cerebrospinal fluid production rates. These data challenge current concepts and suggest that factors other than @entity2657 are the primary cause of the @entity428 elevation 24 hours after @entity64 onset.

title: Intracranial pressure elevation after XXXX in @entity35 : @entity2657 is not the only cause, and short-duration mild @entity2332 is a highly effective preventive therapy.

answer: @entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']


abstract: In both the @entity1 and animal literature, it has largely been assumed that @entity4 is the primary cause of @entity428 ( @entity428 ) elevation after @entity64 and that more @entity4 equates to higher @entity428 . We recently demonstrated a dramatic @entity428 elevation 24 hours after small @entity385 in @entity35 , with minimal @entity4 . This @entity428 elevation was completely prevented by short-duration moderate @entity2332 soon after @entity64 . Here, our aims were to determine the importance of @entity4 in @entity428 elevation after @entity64 and whether mild @entity2332 could prevent the @entity428 rise. @entity64 was performed in @entity35 . @entity428 was monitored and short-duration mild (35   C) or moderate (32.5   C) @entity2332 , or normothermia (37   C) was induced after @entity64 onset. @entity4 was measured in three studies, using wet-dry weight calculations, T2-weighted magnetic resonance imaging, or histology. @entity428 increased 24 hours after @entity64 onset in all normothermic animals. Short-duration mild or moderate @entity2332 prevented this rise. No correlation was seen between   @entity428 and @entity4 or @entity1188 volumes. Calculated rates of @entity4 growth were orders of magnitude less than normal cerebrospinal fluid production rates. These data challenge current concepts and suggest that factors other than @entity2657 are the primary cause of the @entity428 elevation 24 hours after @entity64 onset.

title: Intracranial pressure elevation after @entity385 in XXXX : @entity2657 is not the only cause, and short-duration mild @entity2332 is a highly effective preventive therapy.

answer: @entity35 :: (10116,Species) :: ['rats']